Literature DB >> 28490433

Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-6-Related Impairment of Bone Marrow Function.

Mahan Shahrivari1, Elizabeth Wise1, Micheline Resende1, Jonathan J Shuster1, Jingnan Zhang1, Roberto Bolli1, John P Cooke1, Joshua M Hare1, Timothy D Henry1, Aisha Khan1, Doris A Taylor1, Jay H Traverse1, Phillip C Yang1, Carl J Pepine1, Christopher R Cogle2.   

Abstract

RATIONALE: Intracoronary infusion of bone marrow (BM) mononuclear cells after acute myocardial infarction (AMI) has led to limited improvement in left ventricular function. Although experimental AMI models have implicated cytokine-related impairment of progenitor cell function, this response has not been investigated in humans.
OBJECTIVE: To test the hypothesis that peripheral blood (PB) cytokines predict BM endothelial progenitor cell colony outgrowth and cardiac function after AMI. METHODS AND
RESULTS: BM and PB samples were collected from 87 participants 14 to 21 days after AMI and BM from healthy donors was used as a reference. Correlations between cytokine concentrations and cell phenotypes, cell functions, and post-AMI cardiac function were determined. PB interleukin-6 (IL-6) negatively correlated with endothelial colony-forming cell colony maximum in the BM of patients with AMI (estimate±SE, -0.13±0.05; P=0.007). BM from healthy individuals showed a dose-dependent decrease in endothelial colony-forming cell colony outgrowth in the presence of exogenous IL-1β or IL-6 (P<0.05). Blocking the IL-1R or IL-6R reversed cytokine impairment. In AMI study participants, the angiogenic cytokine platelet-derived growth factor BB glycoprotein correlated positively with BM-derived colony-forming unit-endothelial colony maximum (estimate±SE, 0.01±0.002; P<0.001), multipotent mesenchymal stromal cell colony maximum (estimate±SE, 0.01±0.002; P=0.002) in BM, and mesenchymal stromal cell colony maximum in PB (estimate±SE, 0.02±0.005; P<0.001).
CONCLUSIONS: Two weeks after AMI, increased PB platelet-derived growth factor BB glycoprotein was associated with increased BM function, whereas increased IL-6 was associated with BM impairment. Validation studies confirmed inflammatory cytokine impairment of BM that could be reversed by blocking IL-1R or IL-6R. Together, these studies suggest that blocking IL-1 or IL-6 receptors may improve the regenerative capacity of BM cells after AMI. CLINICAL TRIAL REGISTRATIONS: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00684060.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  bone marrow cells; cell therapy; interleukin-1; interleukin-6; myocardial infarction

Mesh:

Substances:

Year:  2017        PMID: 28490433      PMCID: PMC5508725          DOI: 10.1161/CIRCRESAHA.116.309947

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  41 in total

1.  [Application of multiple limits regression in dealing with nondetects with multiple limits of detect].

Authors:  Xiaojin Yu; Pei Liu; Jie Min; Hong Zhang
Journal:  Wei Sheng Yan Jiu       Date:  2008-11

2.  Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.

Authors:  Ola Kleveland; Gabor Kunszt; Marte Bratlie; Thor Ueland; Kaspar Broch; Espen Holte; Annika E Michelsen; Bjørn Bendz; Brage H Amundsen; Terje Espevik; Svend Aakhus; Jan Kristian Damås; Pål Aukrust; Rune Wiseth; Lars Gullestad
Journal:  Eur Heart J       Date:  2016-05-08       Impact factor: 29.983

3.  Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale.

Authors:  Claudia Zierold; Marjorie A Carlson; Udo C Obodo; Elizabeth Wise; Victor A Piazza; Marshall W Meeks; Rachel W Vojvodic; Sarah Baraniuk; Timothy D Henry; Adrian P Gee; Stephen G Ellis; Lemuel A Moyé; Carl J Pepine; Christopher R Cogle; Doris A Taylor
Journal:  Am Heart J       Date:  2011-12       Impact factor: 4.749

4.  Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.

Authors:  Christopher R Cogle; Elizabeth Wise; Amy M Meacham; Claudia Zierold; Jay H Traverse; Timothy D Henry; Emerson C Perin; James T Willerson; Stephen G Ellis; Marjorie Carlson; David X M Zhao; Roberto Bolli; John P Cooke; Saif Anwaruddin; Aruni Bhatnagar; Maria da Graca Cabreira-Hansen; Maria B Grant; Dejian Lai; Lem Moyé; Ray F Ebert; Rachel E Olson; Shelly L Sayre; Ivonne H Schulman; Raphael C Bosse; Edward W Scott; Robert D Simari; Carl J Pepine; Doris A Taylor
Journal:  Circ Res       Date:  2014-08-18       Impact factor: 17.367

5.  LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Authors:  Jay H Traverse; Timothy D Henry; Douglas E Vaughan; Stephen G Ellis; Carl J Pepine; James T Willerson; David X M Zhao; Lara M Simpson; Marc S Penn; Barry J Byrne; Emerson C Perin; Adrian P Gee; Antonis K Hatzopoulos; David H McKenna; John R Forder; Doris A Taylor; Christopher R Cogle; Sarah Baraniuk; Rachel E Olson; Beth C Jorgenson; Shelly L Sayre; Rachel W Vojvodic; David J Gordon; Sonia I Skarlatos; Lemuel A Moyè; Robert D Simari
Journal:  Tex Heart Inst J       Date:  2010

6.  Population trends in the incidence and outcomes of acute myocardial infarction.

Authors:  Robert W Yeh; Stephen Sidney; Malini Chandra; Michael Sorel; Joseph V Selby; Alan S Go
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

7.  Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats.

Authors:  Alexander Deten; Hans Christian Volz; Wilfried Briest; Heinz-Gerd Zimmer
Journal:  Cardiovasc Res       Date:  2002-08-01       Impact factor: 10.787

8.  Interleukin-1 receptor antagonist (IL-1ra) modulates endothelial cell proliferation.

Authors:  Rachael M Dewberry; Andrea R King; David C Crossman; Sheila E Francis
Journal:  FEBS Lett       Date:  2008-02-20       Impact factor: 4.124

9.  Identification of splenic reservoir monocytes and their deployment to inflammatory sites.

Authors:  Filip K Swirski; Matthias Nahrendorf; Martin Etzrodt; Moritz Wildgruber; Virna Cortez-Retamozo; Peter Panizzi; Jose-Luiz Figueiredo; Rainer H Kohler; Aleksey Chudnovskiy; Peter Waterman; Elena Aikawa; Thorsten R Mempel; Peter Libby; Ralph Weissleder; Mikael J Pittet
Journal:  Science       Date:  2009-07-31       Impact factor: 47.728

10.  Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study.

Authors:  Ramachandran S Vasan; Lisa M Sullivan; Ronenn Roubenoff; Charles A Dinarello; Tamara Harris; Emelia J Benjamin; Douglas B Sawyer; Daniel Levy; Peter W F Wilson; Ralph B D'Agostino
Journal:  Circulation       Date:  2003-03-25       Impact factor: 29.690

View more
  13 in total

Review 1.  Obesity-related cognitive impairment: The role of endothelial dysfunction.

Authors:  Joy Jones Buie; Luke S Watson; Crystal J Smith; Catrina Sims-Robinson
Journal:  Neurobiol Dis       Date:  2019-08-24       Impact factor: 5.996

2.  Associations Between Inflammation, Cardiovascular Regenerative Capacity, and Cardiovascular Events: A Cohort Study.

Authors:  Zakaria Almuwaqqat; Jeong Hwan Kim; Mariana Garcia; Yi-An Ko; Kasra Moazzami; Bruno Lima; Samaah Sullivan; Jamil Alkhalaf; Anurag Mehta; Amit J Shah; Mohammad S Hussain; Brad D Pearce; J Douglas Bremner; Edmund K Waller; Viola Vaccarino; Arshed A Quyyumi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-09-23       Impact factor: 8.311

3.  Mitoprotection attenuates myocardial vascular impairment in porcine metabolic syndrome.

Authors:  Fang Yuan; Ahmad F Hedayat; Christopher M Ferguson; Amir Lerman; Lilach O Lerman; Alfonso Eirin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-01       Impact factor: 4.733

Review 4.  Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease.

Authors:  Maria Dorobantu; Nicoleta-Monica Popa-Fotea; Mihaela Popa; Iulia Rusu; Miruna Mihaela Micheu
Journal:  World J Stem Cells       Date:  2017-12-26       Impact factor: 5.326

5.  Knockout of beta-2 microglobulin reduces stem cell-induced immune rejection and enhances ischaemic hindlimb repair via exosome/miR-24/Bim pathway.

Authors:  Yuqing Zhang; Yanli Wang; Lianbo Shao; Xiangbin Pan; Chun Liang; Bin Liu; Yu Zhang; Wenping Xie; Bing Yan; Feng Liu; Xi-Yong Yu; Yangxin Li
Journal:  J Cell Mol Med       Date:  2019-11-15       Impact factor: 5.310

Review 6.  Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy.

Authors:  Pawan Faris; Sharon Negri; Angelica Perna; Vittorio Rosti; Germano Guerra; Francesco Moccia
Journal:  Int J Mol Sci       Date:  2020-10-07       Impact factor: 5.923

7.  Knockdown of circROBO2 attenuates acute myocardial infarction through regulating the miR-1184/TRADD axis.

Authors:  Tian-Ping Chen; Nai-Ju Zhang; Hong-Ju Wang; Si-Gan Hu; Xu Geng
Journal:  Mol Med       Date:  2021-03-03       Impact factor: 6.354

8.  Hypofunction of Circulating Endothelial Progenitor Cells and Aggravated Severity in Elderly Male Patients With Non-ST Segment Elevation Myocardial Infarction: Its Association With Systemic Inflammation.

Authors:  Lijin Zeng; Cong Zhang; Yuanting Zhu; Zhihao Liu; Gexiu Liu; Bin Zhang; Chang Tu; Zhen Yang
Journal:  Front Cardiovasc Med       Date:  2021-06-17

9.  Decreased Count and Dysfunction of Circulating EPCs in Postmenopausal Hypercholesterolemic Females via Reducing NO Production.

Authors:  Ying Luo; Quan-Neng Yan; Wan-Zhou Wu; Fan-Yan Luo
Journal:  Stem Cells Int       Date:  2018-04-11       Impact factor: 5.443

10.  NF-κB-dependent miR-31/155 biogenesis is essential for TNF-α-induced impairment of endothelial progenitor cell function.

Authors:  Ji-Hee Kim; Ji-Yoon Kim; Minsik Park; Suji Kim; Taesam Kim; Joohwan Kim; Seunghwan Choi; Wonjin Park; Jong Yun Hwang; Jongseon Choe; Kwon-Soo Ha; Moo-Ho Won; Sungwoo Ryoo; Young-Guen Kwon; Young-Myeong Kim
Journal:  Exp Mol Med       Date:  2020-08-07       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.